Single Center Registry of Non-STEMI Acute Coronary Syndrome Patients Treated With Bivalirudin

April 24, 2013 updated by: Minneapolis Heart Institute Foundation

This is a registry of patients with non ST segment elevation Myocardial Infarction (heart attack) and/or unstable acute coronary artery syndrome treated with a standardized protocol including Bivalirudin.

Data will be collected on diagnosis, treatment and outcomes.

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

32

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Minnesota
      • Waconia, Minnesota, United States, 55387
        • Ridgeview Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Emergency Department

Description

Inclusion Criteria:

  • Age ≥ 18
  • Chest pain or symptoms believed to be an anginal equivalent and representing myocardial ischemia, lasting at least 10 minutes within the past 24 hours
  • Having any one of the following:

    1. Ischemic changes on ECG: ST depression >0.5 mm OR T wave inversion >2 mm
    2. Positive cardiac markers
    3. New onset CHF presumed secondary to ischemia
    4. Pulmonary edema
    5. Known coronary artery disease with typical symptoms
    6. Hemodynamic instability
    7. Sustained ventricular tachycardia

Exclusion Criteria:

  • For the purpose of the SSDI, patients will be excluded if we are unable to obtain their Social Security Number.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Non-STEMI ACS

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Incidence of MACE defined as any one of the following: • Acute myocardial infarction/reinfarction • Ischemia-driven unplanned revascularizations • Stroke • All cause Mortality
Time Frame: 30 days
30 days

Secondary Outcome Measures

Outcome Measure
Time Frame
Rehospitalization for ACS
Time Frame: 30 days
30 days
All cause mortality
Time Frame: 30 days, one year and up to 5 years
30 days, one year and up to 5 years
Major Bleeding
Time Frame: in hospital and at 30 days
in hospital and at 30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: David M Larson, MD, Minneapolis Heart Institute Foundation

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2008

Primary Completion (Actual)

December 1, 2011

Study Completion (Actual)

December 1, 2012

Study Registration Dates

First Submitted

February 11, 2009

First Submitted That Met QC Criteria

February 11, 2009

First Posted (Estimate)

February 12, 2009

Study Record Updates

Last Update Posted (Estimate)

April 25, 2013

Last Update Submitted That Met QC Criteria

April 24, 2013

Last Verified

April 1, 2013

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe